Kiniksa Pharmaceuticals International, plc $KNSA Shares Newly Bought by Fonville Wealth Management LLC

Key Points

• Fonville Wealth Management purchased 19,803 Kiniksa Pharmaceuticals shares during the third quarter, valued at approximately $1.48 million. Institutional investors collectively own 53.95% of the company.
• Kiniksa shares rose 2.5% to $97.56, near their 52-week high of $98.36. The company exceeded quarterly expectations, reporting $0.56 in EPS versus $0.37 expected and revenue of $285.97 million versus $260.66 million estimated.
• Analysts maintain a favorable outlook, with seven Buy ratings and two Holds, producing a consensus “Moderate Buy” rating and an average price target of $98.43; several firms recently raised their targets as high as $110.

Fonville Wealth Management LLC purchased a new stake in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 19,803 shares of the company's stock, valued at approximately $1,478,000.

A number of other large investors have also recently modified their holdings of KNSA. Allworth Financial LP grew its holdings in shares of Kiniksa Pharmaceuticals International by 42.0% during the second quarter. Allworth Financial LP now owns 453 shares of the company's stock worth $29,000 after purchasing an additional 134 shares in the last quarter. Arizona State Retirement System increased its position in shares of Kiniksa Pharmaceuticals International by 2.1% in the second quarter. Arizona State Retirement System now owns 10,132 shares of the company's stock worth $648,000 after purchasing an additional 209 shares during the last quarter. GAMMA Investing LLC raised its stake in Kiniksa Pharmaceuticals International by 21.1% in the third quarter. GAMMA Investing LLC now owns 1,278 shares of the company's stock valued at $95,000 after purchasing an additional 223 shares in the last quarter. First Trust Advisors LP raised its stake in Kiniksa Pharmaceuticals International by 3.1% in the first quarter. First Trust Advisors LP now owns 9,876 shares of the company's stock valued at $476,000 after purchasing an additional 293 shares in the last quarter. Finally, Curry Webb Wealth Management LLC bought a new stake in Kiniksa Pharmaceuticals International during the third quarter valued at approximately $29,000. Institutional investors own 53.95% of the company's stock.

Kiniksa Pharmaceuticals International Trading Up 2.5%

Shares of NASDAQ KNSA opened at $97.56 on Friday. The stock has a market cap of $7.61 billion, a price-to-earnings ratio of 75.05 and a beta of 0.04. Kiniksa Pharmaceuticals International, plc has a 1-year low of $36.56 and a 1-year high of $98.36. The stock's 50-day moving average is $78.88 and its 200 day moving average is $59.78.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last issued its earnings results on Tuesday, October 27th. The company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.19. The business had revenue of $285.97 million during the quarter, compared to analyst estimates of $260.66 million. Kiniksa Pharmaceuticals International had a return on equity of 17.27% and a net margin of 11.58%. On average, analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.16 EPS for the current fiscal year.

Insider Activity at Kiniksa Pharmaceuticals International

In other news, CAO Michael Megna sold 4,600 shares of the business's stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the completion of the sale, the chief accounting officer directly owned 29,062 shares in the company, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 51.98% of the company's stock.

Analyst Ratings Changes

A number of research firms have commented on KNSA. Citigroup boosted their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $100.00 and gave the stock a "buy" rating in a research note on Wednesday, July 29th. Wells Fargo & Company raised their price objective on shares of Kiniksa Pharmaceuticals International from $87.00 to $110.00 and gave the company an "overweight" rating in a research report on Wednesday. Wedbush raised their price objective on shares of Kiniksa Pharmaceuticals International from $99.00 to $102.00 and gave the company an "outperform" rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price objective on shares of Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an "overweight" rating in a report on Wednesday, July 29th. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, July 12th. Seven analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $98.43.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company's research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa's principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.

Want to see what other hedge funds are holding KNSA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.